COVID-19 Vaccines - Gambia

Gambia

Highlights

In the Gambia, the revenue in the COVID-19 Vaccines market is projected to reach US$12.96m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of -17.75%, resulting in a market volume of US$4.88m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$4.39bn in 2024.
Despite challenges, Gambia has made significant progress in the distribution and administration of COVID-19 vaccines, ensuring its population's health and safety.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The COVID-19 pandemic has affected the entire world, and Gambia is no exception. The country has seen a significant rise in COVID-19 cases, leading to an increased demand for vaccines. In response to this demand, the government of Gambia has taken steps to secure COVID-19 vaccines for its citizens.

Customer preferences: The citizens of Gambia are showing a high level of interest in COVID-19 vaccines. They are actively seeking information about the vaccines and their availability. The government has been working to educate the public about the vaccines, and this has helped to build trust in the vaccination process.

Trends in the market: The COVID-19 vaccine market in Gambia is still in its early stages. The government has secured a limited number of vaccines, and these are being distributed to priority groups such as healthcare workers and the elderly. The demand for vaccines is expected to increase as more people become aware of their availability.

Local special circumstances: Gambia is a small country with a population of around 2.3 million people. The country has a limited healthcare system, and this has made it difficult to distribute vaccines to all parts of the country. The government is working to overcome these challenges by partnering with international organizations to secure more vaccines and improve the distribution process.

Underlying macroeconomic factors: Gambia is one of the poorest countries in the world, and this has made it difficult for the government to secure COVID-19 vaccines. The country has limited financial resources, and this has made it challenging to compete with wealthier countries for vaccine supplies. Additionally, the country has limited healthcare infrastructure, which has made it difficult to distribute vaccines to all parts of the country. Despite these challenges, the government of Gambia is committed to securing vaccines for its citizens and is working to overcome these obstacles.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.